Stockscreener 앱 받기
7.54
5.40%
-0.43
시간 외 거래:
7.54
Amneal Pharmaceuticals Inc 주식(AMRX)의 최신 뉴스
Amneal targets $3B-$3.1B in 2025 revenue with strong growth drivers - MSN
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Q1 2025 Earnings Call Transcript - Insider Monkey
Amneal Pharmaceuticals Inc (AMRX) Q1 2025 Earnings Call Highlights: Strong Growth and Strategic ... By GuruFocus - Investing.com Canada
Amneal Pharmaceuticals Reports Strong Q1 2025 Results - TipRanks
Amneal: Q1 Earnings Snapshot - MySA
Amneal Q1 2025 slides: Revenue up 5%, EPS surges 50% amid strategic shift - Investing.com Nigeria
Drug Maker Amneal Highlights Strong Commercial Uptake For Parkinson's Drug But Q1 Earnings Are Mixed - Benzinga
Earnings call transcript: Amneal Pharmaceuticals Q1 2025 beats EPS forecasts - Investing.com Nigeria
Amneal Pharmaceuticals, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:AMRX) - Seeking Alpha
Amneal (AMRX) Reports Strong Start in 2025 Despite Missing Reven - GuruFocus
Amneal Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat
Amneal Pharmaceuticals Q1 2025: Revenue Miss but Profit Beats ExpectationsNews and Statistics - IndexBox
Amneal Pharma A earnings beat by $0.06, revenue fell short of estimates - Investing.com Canada
Amneal Pharma Swings To Profit In Q1, Beats Estimates; Affirms FY25 Guidance - Nasdaq
Amneal Reports First Quarter 2025 Financial Results - BioSpace
Amneal Pharmaceuticals (AMRX) Q1 Earnings Beat Estimates - Yahoo Finance
Amneal Pharmaceuticals Reports Strong Q1 2025 Financial Results - TipRanks
Amneal Pharmaceuticals misses revenue estimates, stock falls 3% By Investing.com - Investing.com Nigeria
Amneal Pharmaceuticals Q1 Adjusted Earnings, Revenue Rise; 2025 Outlook Affirmed - marketscreener.com
Amneal (NASDAQ:AMRX) Misses Q1 Sales Targets, Stock Drops 11.3% - Yahoo Finance
Amneal Pharmaceuticals misses revenue estimates, stock falls 3% - Investing.com
(AMRX) Amneal Pharmaceuticals Forecasts Fiscal Year 2025 Adjusted EPS Range $0.65$0.70 - marketscreener.com
Earnings Flash (AMRX) Amneal Pharmaceuticals Posts Q1 Revenue $695.4M, vs. FactSet Est of $714.8M - marketscreener.com
Amneal (AMRX) To Report Earnings Tomorrow: Here Is What To Expect - Yahoo Finance
Press Release Distribution & PR Platform - ACCESS Newswire
Despite recent sales, Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) insiders remain the largest stockholders with 49% ownership - simplywall.st
Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
2 Reasons to Avoid AMRX and 1 Stock to Buy Instead - Yahoo Finance
Parkinson’s Disease Therapeutic Domain Projected to See Transformational Growth Across the 7MM During the Study Period (2020–2034) | DelveInsight - GlobeNewswire Inc.
Amneal Pharmaceutical LLC Issues a Nationwide Recall of Ropivacaine Hydrochloride Injection, USP 500mg/100mL, Due to the Potential Presence of Particulate Matter - usrecallnews.com
Even though Amneal Pharmaceuticals (NASDAQ:AMRX) has lost US$78m market cap in last 7 days, shareholders are still up 125% over 5 years - Yahoo Finance
Is Amneal Pharmaceuticals, Inc. (AMRX) the Best Pharma Stock to Buy for Long Term Growth? - Insider Monkey
Lobbying Update: $60,000 of AMNEAL PHARMACEUTICALS INC. lobbying was just disclosed - Nasdaq
10 Best Pharma Stocks to Buy for Long Term Growth - Insider Monkey
Amneal donates $1.5M this Parkinson’s Awareness Month - NJBIZ
NY AG reaches $270M multistate opioid settlement with Amneal Pharmaceuticals - Class Action Lawsuits
Amneal Donates $1.5 Million to Support Patients During Parkinson’s Awareness Month - BioSpace
Amneal's $1.5M Donation Makes Parkinson's Medications More Accessible for Thousands - Stock Titan
Amneal to Report First Quarter 2025 Results on May 2, 2025 - Bluefield Daily Telegraph
Amneal Launches Boruzu for Multiple Myeloma and Mantle Cell Lymphoma - Clinical Oncology News
Amneal’s CREXONT improves sleep in Parkinson’s patients By Investing.com - Investing.com South Africa
Amneal's Combination Drug Shows Improved Sleep Quality In Parkinson's Disease Patients - Benzinga
Amneal Announces New Data from Phase 3 Study Showing Significant Improvements in Sleep Quality with CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Parkinson’s Disease - BioSpace
Amneal Announces New Data From Phase 3 Study - marketscreener.com
Amneal’s CREXONT improves sleep in Parkinson’s patients - Investing.com
Breakthrough: New Parkinson's Drug Shows Major Sleep Quality Gains in Phase 3 Trial - Stock Titan
Amneal Boruzu Subcutaneous Formulation Launch - Specialty Pharmacy Continuum
1.20%
0.06%
자본화:
|
볼륨(24시간):